We conducted a secondary analysis of a completed study of the differential efficacy and side
effects of aripiprazole versus haloperidol in early-stage schizophrenia (ESS), a …

Aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia. It is a D2
receptor partial agonist with partial agonist activity at 5-HT1A receptors and antagonist …

Objective: To evaluate the efficacy of aripiprazole across a range of symptoms—positive,
negative, disorganized thought, depression/anxiety, and hostility—in schizophrenia and …

Introduction: Aripiprazole, a dopamine D2 receptor partial agonist, has also partial agonist
activity at serotonin (5-HT) 1A receptors and antagonist activity at 5-HT2A receptors …

OBJECTIVE: To examine the efficacy of aripiprazole across symptoms in patients with acute
exacerbation of schizophrenia or schizoaffective disorder. METHODS: Data were pooled …

BACKGROUND: Few studies have directly compared the efficacy and tolerability of atypical
agents. METHODS: This multicenter, randomized, double-blind study compared the efficacy …

Background: Aripiprazole is an investigational agent for treating schizophrenia that has a
novel pharmacologic profile. The present study investigated the efficacy, safety, and …

Objective To compare the long-term efficacy and safety of aripiprazole with olanzapine in
patients with either acute relapsing or chronic, stable schizophrenia. Materials and methods …

BACKGROUND: The Remission in Schizophrenia Working Group (RSWG) has defined
criteria for symptomatic remission based on achieving and maintaining a consistently low …

Objective: To evaluate the effectiveness of olanzapine versus aripiprazole in patients with
schizophrenia. Method: Patients aged 18 to 65 years with schizophrenia (diagnosed …